Theranexus Logo

Theranexus

A biopharma developing drugs for rare neurological diseases by targeting non-neuronal cells.

ALTHX | PA

Overview

Corporate Details

ISIN(s):
FR0013286259
LEI:
969500BFCV6IC7MFQP20
Country:
France
Address:
60 AVENUE ROCKEFELLER, 69008 LYON
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Theranexus is an innovative, clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company develops drug candidates for the treatment of rare neurological and central nervous system (CNS) diseases. It leverages a unique platform for the identification and characterization of advanced therapy drug candidates, focusing on the key role of non-neuronal cells (glial cells) to enhance therapeutic efficacy. The company's pipeline includes a drug candidate in clinical development for Batten disease.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-29 18:30
Regulatory News Service
Theranexus devient THX Pharma : une évolution stratégique vers la commercialisa…
French 211.7 KB
2025-09-29 18:30
Regulatory News Service
Theranexus Becomes THX Pharma: A Strategic Evolution Toward the Commercializati…
English 209.9 KB
2025-05-13 18:00
Regulatory News Service
THERANEXUS AND BEYOND BATTEN DISEASE FOUNDATION ANNOUNCE STRONG POSITIVE REAL-W…
English 391.8 KB
2025-05-13 18:00
Business and Financial Review
THERANEXUS ET LA FONDATION BEYOND BATTEN DISEASE ANNONCENT DES DONNÉES EN VIE R…
French 352.9 KB
2025-04-29 19:05
Registration Form
URD 2024
French 10.6 MB
2025-04-29 19:00
Earnings Release
THERANEXUS PUBLISHES ITS 2024 FULL-YEAR RESULTS, PRESENTS ITS PROGRESS REPORT A…
English 336.5 KB
2025-04-29 19:00
Earnings Release
THERANEXUS PUBLIE SES RÉSULTATS ANNUELS 2024, FAIT LE POINT SUR SES ACTIVITÉS E…
French 297.3 KB
2025-03-06 18:00
Regulatory News Service
MODIFICATION DU CONTRAT DE LIQUIDITÉ CONFIÉ À PORTZAMPARC
French 272.5 KB
2025-01-23 18:15
Report Publication Announcement
THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2025
English 262.8 KB
2025-01-23 18:00
Report Publication Announcement
THERANEXUS PUBLIE SON AGENDA FINANCIER POUR L'EXERCICE 2025
French 254.5 KB
2025-01-16 18:00
Declaration of Voting Results & Voting Rights Announcements
Information mensuelle relative au nombre total de droits de vote et d'actions c…
French 168.8 KB
2025-01-09 18:00
Report Publication Announcement
THERANEXUS ANNOUNCES THE PUBLICATION OF ITS LETTER TO SHAREHOLDERS
English 179.9 KB
2025-01-09 18:00
Report Publication Announcement
THERANEXUS ANNONCE LA PUBLICATION DE SA LETTRE AUX ACTIONNAIRES
French 181.7 KB
2024-12-17 18:15
Capital/Financing Update
THERANEXUS PRESENTS AN UPDATE OF ITS CASH POSITION AND FINANCING HORIZON
English 212.3 KB
2024-12-17 18:15
Capital/Financing Update
THERANEXUS FAIT UN POINT SUR SA POSITION DE TRÉSORERIE ET SON HORIZON DE FINANC…
French 230.9 KB

Automate Your Workflow. Get a real-time feed of all Theranexus filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Theranexus via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
A tech group providing R&D, services, training, and investment for life sciences industries.
Spain IKM
AI-powered genome sequencing and reanalysis to diagnose rare diseases globally.
South Korea 394800
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea 174900
Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.
South Korea 203400
ABL Bio Inc. Logo
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
South Korea 298380
Acticor Biotech Logo
Clinical-stage biopharma developing a first-in-class drug for thrombotic diseases like stroke.
France ALACT
Adecco Group AG Logo
Global talent solutions firm offering staffing, placement, career transition, and tech consulting.
Switzerland ADI1
ADforus Co., Ltd. Logo
Ad-tech firm with AI platforms for mobile marketing and publisher monetization solutions.
South Korea 397810
Adocia Logo
Biotech improving protein drug formulations for diabetes & obesity and developing cell therapies.
France ADOC
ad pepper media International N.V. Logo
Global performance marketing & audience targeting solutions for advertisers and agencies worldwide.
Germany APM

Talk to a Data Expert

Have a question? We'll get back to you promptly.